Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM2 | Q14416 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17087400 | 0.81 | KDM4E (0.46) | LMNASMN1; SMN2KDM4E | |
| SCHEMBL17518316 | 0.78 | KMT2A (0.35) | LMNASMN1; SMN2KDM4E | |
| SCHEMBL17518377 | 0.77 | DPP4 (0.30) | — | |
| SCHEMBL17524661 | 0.76 | — | — | |
| SCHEMBL17518320 | 0.76 | KDM4E (0.41) | LMNASMN1; SMN2KDM4E | |
| SCHEMBL17518388 | 0.76 | L3MBTL1 (0.46) | LMNASMN1; SMN2 | |
| SCHEMBL27619858 | 0.76 | L3MBTL1 (0.46) | GRM2SMN1; SMN2KDM4E | |
| SCHEMBL17518319 | 0.75 | — | — | |
| SCHEMBL17518309 | 0.75 | L3MBTL1 (0.49) | LMNASMN1; SMN2 | |
| SCHEMBL17087480 | 0.75 | PAOX (0.37) | LMNASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160039880-A1 | CYCLOSPORIN A ANALOGS | ALLERGAN, INC. | 2016-02-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160039880-A1 | CYCLOSPORIN A ANALOGS | TSLP, CHP1, PPP3R1 | GRM2 4774/4885LMNA 3956/4885SMN1; SMN2 4451/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.